TNFRSF9 Antibody, HRP conjugated

1. A study on a northern Chinese Han population examined the association of 3 SNPs (rs161827, rs161818, and rs161810) of the CD137 gene with ischemic stroke. The study revealed that rs161827 differed significantly between patients with and without diabetes and the controls. rs161818 and rs161810 differed significantly between patients without diabetes and the controls. Notably, all 3 SNPs were statistically significant in the combined stroke group. PMID: 28755037
2. LOAd703, a designed adenovirus equipped with trimerized CD40L and 4-1BBL, has been developed to activate the CD40 and 4-1BB pathways, respectively. PMID: 28536305
3. Constant 4-1BB costimulation in chimeric antigen receptors can impede T cell survival, and this effect is vector-dependent. PMID: 28978471
4. Cetuximab-mediated NK-cell expression of CD137 on tumor-infiltrating lymphocytes is contingent upon FcgammaRIIIa polymorphism. In patients with head and neck cancer who received neoadjuvant cetuximab, upregulation of CD137 by intratumoral, cetuximab-activated NK cells correlated with FcgammaRIIIa V/F polymorphism and predicted clinical response. PMID: 27496866
5. In this research, we systematically evaluated a range of CAR constructs targeting glypican-3 (GPC3), which is selectively expressed on several solid tumors. We compared GPC3-specific CARs that encoded CD3zeta (Gz) alone or with costimulatory domains derived from CD28 (G28z), 4-1BB (GBBz), or CD28 and 4-1BB (G28BBz). PMID: 27530312
6. 4-1BB and 4-1BBL serve as markers for predicting patient prognosis and represent a valuable screening target for patients with acute myeloid leukemia at initial diagnosis. PMID: 27388616
7. Further investigation explored the role of CD137-CRDI (cysteine-rich domain I) in the binding of CD137-CD137L. PMID: 27430526
8. Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8(+) TIL. PMID: 28115575
9. Findings indicate that CD137 antigen is a useful marker for identifying Mycobacterium tuberculosis (Mtb)-reactive CD4(+) T cells (Mtb-reactive CD4(+) T cells) using flow cytometry. PMID: 28218958
10. Anti-4-1BB single chain variable fragments enhanced surface CD69 expression and interleukin-2 production in stimulated CCRF-CEM cells, confirming the agonistic effect of the selected single chain variable fragments. These findings provide a basis for future research into the biological functions of anti-4-1BB single chain variable fragments. PMID: 28347235
11. Studies suggest that adoptive T cell therapy and CD137 antigen hold significant potential for enhancing the efficacy of current cancer immunotherapies. PMID: 26970765
12. In complex with T cell receptor, CD137 promotes the formation of memory T cells, cell respiration, fatty acid oxidation, and mitochondrial biogenesis. PMID: 26885860
13. These studies provide the first direct evidence that the ligation of tumor necrosis factor superfamily members and their cognate receptors is crucial for controlling viral lytic replication. PMID: 26467721
14. Our findings reveal a novel, TNFRSF9-positive, reactive astrocytic phenotype in human gliomas. PMID: 24606203
15. Human genetic evidence supports the involvement of CD137 in atherosclerosis. PMID: 25032953
16. Upon activation, transferred human T lymphocytes express the inducible surface antigens hPD-1 and hCD137 on their plasma membrane. PMID: 26113085
17. Our findings provide biological explanations for the antitumor effects of CD19 CARs and the observation that CD19 CAR T cells incorporating the 4-1BB costimulatory domain exhibit greater persistence than those incorporating CD28 in clinical trials. PMID: 25939063
18. Upregulation of CD137 expression through LMP1 by EBV promotes cell survival in T or NK cells. PMID: 25409517
19. Classification can be based on CD137 or CD154 expression. PMID: 25367298
20. High expression of CD137 is associated with type 1 diabetes. PMID: 24797972
21. DENV C disrupts Daxx and NF-kappaB interaction to induce CD137-mediated apoptosis during DENV infection. PMID: 25019989
22. The action of agonist anti-4-1BB in suppressing autoimmune and allergic inflammation was entirely dependent on Galectin-9 (Gal-9). Gal-9 directly bound to 4-1BB, at a site distinct from the binding site of antibodies and the natural ligand of 4-1BB. PMID: 24958847
23. A role for the TNFR-family member CD137 in the immunobiology of human cancer, where it is preferentially expressed on a tumor-reactive subset of tumor-infiltrating lymphocytes. PMID: 24045181
24. Monocytes interact with iNKT cells to increase the expression of 4-1BBL and 4-1BB, and in conjunction with this pathway, maintain their baseline numbers. PMID: 24639347
25. Findings demonstrate that immunohistochemistry for CD137L can reliably distinguish small B-cell lymphomas from reactive lymphoid aggregates. PMID: 24746207
26. Dengue virus induces CD137 signaling to enhance apoptosis by increasing TNF-alpha production via activation of p38 MAPK. PMID: 23557259
27. This study is the first to show that SAHA treatment modulates CD137 in breast cancer cells. PMID: 22797667
28. The CD137 multi-parameter flow cytometry fast assay enables phenotypic and functional determination of alloreactive precursor frequencies of both CD4+ and CD8+ T cells with high sensitivity and specificity. PMID: 23750604
29. Co-stimulation through 4-1BB/CD137 enhances the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PMID: 23560068
30. Collectively, these data provide evidence that the 4-1BB signal is a significant regulator of gammadelta T cells. PMID: 23640752
31. The mechanisms underlying the effect of CD137 signaling on TNF-alpha production involve a decrease in TNF-alpha production by antigen-presenting cells (APCs) and, possibly, an increase in APC apoptosis. PMID: 23437083
32. Our results unveil a new regulatory mechanism for CD137L expression that mediates immune escape by HRS cells, identifying CD137 as a potential target for Hodgkin immunotherapy. PMID: 23204227
33. Patients with head and neck cancer exhibit decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB. PMID: 22204816
34. 4-1BB (CD137), along with CD103, distinguishes mesenteric lymph node dendritic cells (DCs) with the highest level of retinal dehydrogenase (RALDH) activity. Ligation of 4-1BB maintains RALDH expression in these gut DCs. PMID: 22896640
35. CD137 protein is expressed by a specific group of hematolymphoid tumors, including classical Hodgkin lymphoma, T-cell and NK/T-cell lymphomas, and follicular dendritic cells neoplasms. PMID: 22901750
36. Treatment with a CD137 agonistic antibody induces CCL21 expression and DC accumulation near lymphatic vessels. Collectively, these findings demonstrate that the inflammatory function of lymphatic vessels can be regulated by CD137. PMID: 22593548
37. CD137:CD137L interactions regulate the innate and adaptive immune response of the host against M. tuberculosis. PMID: 21747409
38. A significant positive correlation exists between CD137 expression and complex coronary stenosis morphology. PMID: 21396356
39. Data suggest that 4-1BBL mediates NK-cell immunosubversion in CLL, potentially contributing to the reported compromised efficacy of Rituximab in inducing NK-cell reactivity in this disease. PMID: 22144129
40. CD137 activity is directly proportional to colorectal cancer stage. Surgical resection of the tumor results in increased CD134 and CD137 expression. PMID: 22343199
41. We demonstrate that the inflammatory and cytotoxic function of CD4(+)CD28(null) T cells can be inhibited by blocking OX40 and 4-1BB costimulatory receptors. PMID: 22282196
42. sCD137 levels correlate with the probability of complications and lethality. The association of sCD137, a product of activated T cells, with the severity of acute pancreatitis suggests that T cells contribute to the pathogenesis of acute pancreatitis. PMID: 21963611
43. CD137 plays a role in breast cancer, and its specific antibody can be used to enhance trastuzumab efficacy. PMID: 22326955
44. Conditioned medium from Lewis Lung Carcinoma cells caused significant upregulation of 4-1BB in mast cells. PMID: 22343053
45. Data indicate that ex4-1BBL augments 4-1BB expression not only on the primed T cell but also on DCs. PMID: 21745658
46. Measuring a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9) powerfully predicts overall survival in patients with diffuse large B-cell lymphoma. PMID: 21670469
47. This work is the first to demonstrate the contribution of CD137 signaling to DENV-mediated apoptosis. PMID: 21669186
48. CD137 ligand can also be expressed as a transmembrane protein on the cell surface and transmit signals into the cells on which it is expressed (reverse signaling). PMID: 20643812
49. Results suggest a two-step model of M cell differentiation, with initial CD137-independent commitment to the M cell lineage followed by CD137-CD137L interaction of M cells with CD137-activated B cells or dendritic cells for functional maturation. PMID: 20616340
50. Data support a role for CD137 in the recruitment of monocytes to inflammatory tissues. PMID: 20347151

Show More

Hide All

HGNC: 11924

OMIM: 602250

KEGG: hsa:3604

STRING: 9606.ENSP00000366729

UniGene: Hs.738942